Clinical Trial

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Study acronym: MAESTRA 2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Protocol Amendment History 8 changes
notable Trial sites expanded: 178 -> 181 locations 2026-08-07
notable Trial sites expanded: 169 -> 178 locations 2026-07-24
notable Trial sites reduced: 177 -> 169 locations 2026-07-21
notable Trial sites expanded: 172 -> 177 locations 2026-07-07
notable Trial sites expanded: 167 -> 172 locations 2026-07-01
notable Trial sites expanded: 162 -> 165 locations 2026-05-27
notable Trial sites expanded: 157 -> 162 locations 2026-05-09
notable Trial sites expanded: 139 -> 155 locations 2026-04-15
Trial Details
NCT Number NCT07214779
Lead Sponsor Incyte Corporation
Collaborators: ENGOT Foundation, GOG Foundation
Conditions Ovarian Cancer
Enrollment 466 participants
Start Date 2025-12-09
Primary Completion 2028-11-15 (estimated)
Study Completion 2029-05-14 (estimated)
Updated on ClinicalTrials.gov 2026-08-06